Overall, these results demonstrated the administration of ReACp53 resulted in a reduced tumor burden in mice bearing OVCAR3 human ovarian cancer cells, but not p53-null SKOV3 cells using a physiologic intraperitoneal disease model. This evidence concerns the gene TP53 and ovarian cancer.